Total
Exposed (400) Non-exposed (400)
p-value
Gender 368M/432F 184M/216F 184M/216F 0.504
Median Age, Q1 - Q3 60, 46 - 68 64, 55.75 - 70 < 0.0001#
Events 37* | 4.6% 5 | 1.25% 32 | 8% < 0.00001
Mean montelukast exposure
7.83 months
Residence
Rural 139 | 17% 108 | 27% 31 | 8% < 0.00001
Urban 661 | 83% 292 | 73% 369 | 92%
Educational level
Low 242 | 30% 68 | 17% 174| 43.5% < 0.00001
Mid + High 558 | 70% 332 | 83% 226 | 56.5%
Income
Low 371 | 46% 175 | 44% 196| 49% 0.08
Mid + High 429 | 54% 225 | 56% 204 | 51%
Drug prescription
Antihypertensive 399 | 49.9% 198 | 49.5% 201 | 50.25% 0.89
Antiplatelet 59 |7.37% 20 | 5% 39 | 9.75% 0.01
Diuretic 167 | 20.87% 84 | 21% 83 | 20.75% 0.99
Antipsychotic 3 | 0.37% 0 3 | 0.75% 0.25
Antiandrogens 16 | 2% 5 | 1.25% 11 | 2.75 0.21
Antithyroid 7 | 0.875 3 | 0.75% 4 | 1% 0.99
Anti-hypercholesterolemic 132 | 16.5% 58 | 14.5% 74 | 18.5% 0.15
Antihistamines 9 | 1.125% 4 | 1% 5 | 1.25% 0.99
Antipeptics 3 | 0.375% 0 3 | 0.75% 0.24
Antiarrythmics 4 | 0.5% 1 | 0.25% 3 | 0.75% 0.62
Antianemics 2 | 0.25% 0 2 | 0.5% 0.48
Hypoglycemics 49 | 6.125% 20 | 5% 29 | 7.25% 0.24
Antiepileptics 2 | 0.25% 0 0 0.48
Antitumorals 7 | 0.875% 0 7 | 1.75% 0.022
Antibiotics 3 | 0.375% 0 3 | 0,75% 0.25
Antidepressants 1 | 0.125% 0 1 | 0.25 0.99
CV risk 415| 51.87% 206| 51.5% 209| 52.25% 0.89